vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and AMICUS THERAPEUTICS, INC. (FOLD). Click either name above to swap in a different company.
AdvanSix Inc. is the larger business by last-quarter revenue ($359.9M vs $185.2M, roughly 1.9× AMICUS THERAPEUTICS, INC.). AMICUS THERAPEUTICS, INC. runs the higher net margin — 0.9% vs -0.8%, a 1.7% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 9.4%). AdvanSix Inc. produced more free cash flow last quarter ($36.1M vs $16.0M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 3.4%).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
ASIX vs FOLD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $185.2M |
| Net Profit | $-2.8M | $1.7M |
| Gross Margin | 7.6% | 85.7% |
| Operating Margin | -0.7% | 8.6% |
| Net Margin | -0.8% | 0.9% |
| Revenue YoY | 9.4% | 23.7% |
| Net Profit YoY | -892.9% | -88.5% |
| EPS (diluted) | $-0.11 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $359.9M | $185.2M | ||
| Q3 25 | $374.5M | $169.1M | ||
| Q2 25 | $410.0M | $154.7M | ||
| Q1 25 | $377.8M | $125.2M | ||
| Q4 24 | $329.1M | $149.7M | ||
| Q3 24 | $398.2M | $141.5M | ||
| Q2 24 | $453.5M | $126.7M | ||
| Q1 24 | $336.8M | $110.4M |
| Q4 25 | $-2.8M | $1.7M | ||
| Q3 25 | $-2.6M | $17.3M | ||
| Q2 25 | $31.4M | $-24.4M | ||
| Q1 25 | $23.3M | $-21.7M | ||
| Q4 24 | $352.0K | $14.7M | ||
| Q3 24 | $22.3M | $-6.7M | ||
| Q2 24 | $38.9M | $-15.7M | ||
| Q1 24 | $-17.4M | $-48.4M |
| Q4 25 | 7.6% | 85.7% | ||
| Q3 25 | 6.8% | 88.5% | ||
| Q2 25 | 14.3% | 90.2% | ||
| Q1 25 | 14.2% | 90.7% | ||
| Q4 24 | 3.4% | 90.1% | ||
| Q3 24 | 14.4% | 90.6% | ||
| Q2 24 | 17.9% | 91.1% | ||
| Q1 24 | 0.9% | 87.7% |
| Q4 25 | -0.7% | 8.6% | ||
| Q3 25 | -0.9% | 20.3% | ||
| Q2 25 | 7.7% | -6.1% | ||
| Q1 25 | 7.7% | -6.3% | ||
| Q4 24 | -3.9% | 10.7% | ||
| Q3 24 | 7.5% | 15.3% | ||
| Q2 24 | 11.5% | 11.8% | ||
| Q1 24 | -7.0% | -25.1% |
| Q4 25 | -0.8% | 0.9% | ||
| Q3 25 | -0.7% | 10.2% | ||
| Q2 25 | 7.7% | -15.8% | ||
| Q1 25 | 6.2% | -17.3% | ||
| Q4 24 | 0.1% | 9.8% | ||
| Q3 24 | 5.6% | -4.8% | ||
| Q2 24 | 8.6% | -12.4% | ||
| Q1 24 | -5.2% | -43.9% |
| Q4 25 | $-0.11 | $0.00 | ||
| Q3 25 | $-0.10 | $0.06 | ||
| Q2 25 | $1.15 | $-0.08 | ||
| Q1 25 | $0.86 | $-0.07 | ||
| Q4 24 | $0.02 | $0.05 | ||
| Q3 24 | $0.82 | $-0.02 | ||
| Q2 24 | $1.43 | $-0.05 | ||
| Q1 24 | $-0.65 | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $293.5M |
| Total DebtLower is stronger | — | $392.7M |
| Stockholders' EquityBook value | $815.2M | $274.2M |
| Total Assets | $1.7B | $949.9M |
| Debt / EquityLower = less leverage | — | 1.43× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.8M | $293.5M | ||
| Q3 25 | $23.7M | $263.8M | ||
| Q2 25 | $18.4M | $231.0M | ||
| Q1 25 | $8.3M | $250.6M | ||
| Q4 24 | $19.6M | $249.9M | ||
| Q3 24 | $17.3M | $249.8M | ||
| Q2 24 | $12.1M | $260.1M | ||
| Q1 24 | $20.6M | $239.6M |
| Q4 25 | — | $392.7M | ||
| Q3 25 | — | $392.0M | ||
| Q2 25 | — | $391.3M | ||
| Q1 25 | — | $390.7M | ||
| Q4 24 | — | $390.1M | ||
| Q3 24 | — | $389.5M | ||
| Q2 24 | — | $388.9M | ||
| Q1 24 | — | $388.4M |
| Q4 25 | $815.2M | $274.2M | ||
| Q3 25 | $818.2M | $230.4M | ||
| Q2 25 | $823.7M | $204.3M | ||
| Q1 25 | $794.4M | $193.6M | ||
| Q4 24 | $774.6M | $194.0M | ||
| Q3 24 | $766.4M | $178.8M | ||
| Q2 24 | $746.6M | $132.5M | ||
| Q1 24 | $713.2M | $130.7M |
| Q4 25 | $1.7B | $949.9M | ||
| Q3 25 | $1.7B | $868.8M | ||
| Q2 25 | $1.6B | $815.3M | ||
| Q1 25 | $1.6B | $789.8M | ||
| Q4 24 | $1.6B | $785.0M | ||
| Q3 24 | $1.5B | $786.6M | ||
| Q2 24 | $1.5B | $749.5M | ||
| Q1 24 | $1.5B | $721.8M |
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.02× | ||
| Q4 24 | — | 2.01× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 2.93× | ||
| Q1 24 | — | 2.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | $16.3M |
| Free Cash FlowOCF − Capex | $36.1M | $16.0M |
| FCF MarginFCF / Revenue | 10.0% | 8.6% |
| Capex IntensityCapex / Revenue | 7.7% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 9.62× |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | $29.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.7M | $16.3M | ||
| Q3 25 | $26.6M | $35.7M | ||
| Q2 25 | $21.1M | $-26.5M | ||
| Q1 25 | $11.4M | $7.8M | ||
| Q4 24 | $64.2M | $-3.9M | ||
| Q3 24 | $57.3M | $-23.0M | ||
| Q2 24 | $50.2M | $22.7M | ||
| Q1 24 | $-36.2M | $-29.7M |
| Q4 25 | $36.1M | $16.0M | ||
| Q3 25 | $66.0K | $35.3M | ||
| Q2 25 | $-7.2M | $-28.9M | ||
| Q1 25 | $-22.6M | $7.5M | ||
| Q4 24 | $29.8M | $-4.2M | ||
| Q3 24 | $26.8M | $-23.3M | ||
| Q2 24 | $16.7M | $21.6M | ||
| Q1 24 | $-71.6M | $-31.5M |
| Q4 25 | 10.0% | 8.6% | ||
| Q3 25 | 0.0% | 20.9% | ||
| Q2 25 | -1.7% | -18.7% | ||
| Q1 25 | -6.0% | 6.0% | ||
| Q4 24 | 9.1% | -2.8% | ||
| Q3 24 | 6.7% | -16.5% | ||
| Q2 24 | 3.7% | 17.0% | ||
| Q1 24 | -21.3% | -28.5% |
| Q4 25 | 7.7% | 0.2% | ||
| Q3 25 | 7.1% | 0.2% | ||
| Q2 25 | 6.9% | 1.6% | ||
| Q1 25 | 9.0% | 0.2% | ||
| Q4 24 | 10.4% | 0.2% | ||
| Q3 24 | 7.7% | 0.3% | ||
| Q2 24 | 7.4% | 0.9% | ||
| Q1 24 | 10.5% | 1.6% |
| Q4 25 | — | 9.62× | ||
| Q3 25 | — | 2.06× | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 182.29× | -0.27× | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
